Skip to main content
Premium Trial:

Request an Annual Quote

Crown Bioscience, Cambridge Quantum Computing Partner on Cancer Biomarker Discovery

NEW YORK — Drug discovery and development firm Crown Bioscience has partnered with Cambridge Quantum Computing (CQC) on the identification of novel cancer treatment biomarkers, the companies said on Wednesday.

Under the terms of the deal, the companies will combine UK-based CQC's quantum machine algorithms and software development capabilities with CrownBio's preclinical and translational research expertise and datasets to identify multi-gene biomarkers that can be used in cancer drug discovery.

Additional terms were not disclosed.

"The agreement continues CrownBio's commitment to innovation and the application of technology to accelerate and de-risk drug development, leading to stronger drug candidates and a more rapid transition from preclinical phases to the clinic," CrownBio CE Armin Spura said in a statement.

San Diego-based CrownBio is a unit of JSR Life Sciences.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.